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ABSTRACT
Objective: This research aims to apply the Visual Basic.Net (VB.NET) of individual dose calculations based on the formula of pharmacokinetics for 
diabetic patients of chronic renal disorder complication in Dr. Pirngadi Hospital because the dosage administered was not based on the patient’s 
creatinine clearance.
Methods: This descriptive research was conducted using a simulated creatinine cleavage calculation using VB.NET programming language applications 
with variable patient data, the value of creatinine, the name of drug, and dosage.
Results: This study used visual basic.net applications and obtained data on drug use 40 patients consisting of 40% male and 60% female, age 41-70 
years, creatinine clearance <50 mL/min. There are 4 types of drugs over the dose based on creatinine clearance calculations of ceftriaxone (18 of 18 
cases), furosemide (19 of 19 cases), ciprofloxacin (2 of 8 cases), and ranitidine (4 of 24 cases). There are 2 types of drugs that are less than the dose 
of pharmacokinetic calculations of metformin (2 of 7 cases) and captopril (16 of 16 cases).
Conclusions: Research has successfully implemented visual basic.net. to calculate the individual dose of patients with complicated diabetic kidney 
failure quickly and easily.
Keywords: Visual Basic.Net, Drug dosage, Pharmacokinetic calculations.
NTRODUCTION
Diabetes mellitus (DM) is one of the health problems that affect 
productivity and can decrease the quality of human resources that its 
prevalence will continue to increase from year to year. DM is a degenerative 
disease characterized by hyperglycemia associated with abnormalities of 
carbohydrate metabolism, fats, and proteins caused by decreased insulin 
sensitivity or both and leads to complications [1]. Complications include 
frequent microvascular complications of diabetic nephropathy, i.e., kidney 
DM complications that may end up as renal failure. Kidney failure can 
occur as a result of the disease itself and may result from the long-term 
use of DM drugs. Drugs expressed through the kidneys will accumulate 
in the presence of impaired renal function and may cause toxic effects or 
worsen the patient’s renal condition if the dose is not adjusted [2].
Most water-soluble drugs are excreted in a certain amount in the intact 
form through the kidneys. Doses of these drugs, especially those with 
narrow therapeutic window drugs, need careful adjustment when 
prescribed to patients with decreased renal function [3]. Accumulation 
of plasma drug levels may occur and minimum toxic levels may be missed 
if doses are not calculated on the patient’s renal function. Most drugs 
also have a damaging effect on the kidneys (nephrotoxic), so the dosage 
should also be adjusted for patients with decreased renal function [4].
Dose adjustment strategies in patients with renal failure may be helpful 
in individual drug therapy and may prevent further deterioration 
in the quality of life of the patient [5]. The recommended method of 
adjusting the dose is to reduce the dose, extend the dose interval, or 
a combination of both [6]. Clinical pharmacokinetics is an application 
of the pharmacokinetic method for drug therapy which includes a 
multidisciplinary approach to individual optimal dosing strategies based 
on patient disease conditions and specific patient considerations [2].
The success rate of diabetes therapy not only provides patient 
guarantees about rational treatment alone but also knowledge of 
clinical pharmacokinetic aspects is also very important to ensure that 
drugs used so as to relieve renal work and drug effectiveness can be 
achieved. Long-term diabetes drug therapy should be followed by 
monitoring of renal function by looking at creatinine clearance so that 
dose adjustment can be made if kidney function declines [7].
The principle of pharmacokinetics in humans aims at making individual 
dosage regimens by optimizing therapeutic response to treatment and 
minimizing side effects. Pharmacokinetics is a branch of pharmacology 
that is associated with the determination of the fate of the drug in the body, 
which includes absorbs, distribution, metabolism, and excretion. Clinical 
pharmacokinetics is the application of pharmacokinetic principles to the 
safe and effective management of drug therapy in a patient so that the 
success of drug therapy can be optimal [1]. The use of antidiabetic drugs 
in renal impairment is necessary in clinical pharmacokinetic principle 
because with the occurrence of kidney degradation, the drugs expressed 
through the kidneys will accumulate and may cause toxic effects or 
worsen the patient’s renal condition, so dose adjustment is necessary [2].
Visual Basic.Net (VB.NET) is one of the high-level computer programming 
languages. One programming language is the object-oriented program or 
object-oriented programming. The word “Visual” shows the way that is 
used to create a graphical user interface. Now, Microsoft has been able 
to realize the vision of “Windows operating system in every PC and PC 
in every desktop.” One tool for developing.NET applications is Microsoft 
VB.NET. VB.NET along with Visual C++.NET, Visual C#.NET, Visual J++.
NET, and Visual J#.NET is a part of Microsoft Visual Studio.NET. VB.NET 
can also work with database applications that can hold data using SQL 
server. Excess VB.NET is used for calculation of individual doses based on 
creatinine clearance, so it can be easily applied to health facilities [8]. This 
research aims to apply the VB.NET of individual dose calculations based 
on the formula of pharmacokinetics for diabetic patients of chronic renal 
disorder complication in Dr. Pirngadi Hospital because so far the dosage 
administered was not based on the patient’s creatinine clearance.
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MATERIALS AND METHODS
The study was conducted at Dr. Pirngadi Hospital Medan on July–
August 2017. The patient data were collected in a limited population 
at the inpatient hospital in RSUD Dr.Pirngadi Medan. The inclusion 
criteria were patients with a diagnosis of acute and chronic renal 
failure, patients with creatinine clearance <80 mL/min, and patients 
receiving drug therapy were eliminated mainly through the kidneys. 
Patients with a diagnosis of diabetes complication of renal failure 
are identified, treatment data along with laboratory data. Next, we 
calculated the creatinine clearance value with an equation that matched 
the available data and the general condition of the patient. The methods 
used in creatinine clearance calculations include the Cockroft and 
Gault formula (Method 1), the Jellife and Jellife formula (Method 2) 
specifically for patients with unstable creatinine serum values, and 
Salazar and Corcoran formula (Method 3) formulas for obese patients. 
After creatinine clearance was calculated by an appropriate equation, 
a dosage adjustment calculation for drugs excreted primarily through 
the kidneys, a class of nephrotoxic drugs and a class of drugs with a 
narrow therapeutic index secreted through the kidneys. The method 
that can be used in dose adjustment is the method of drug excretion 
fraction in the intact form. The dose adjustment was calculated using 
the Giusti–Hayton formula using the fraction drug values expressed in 
whole form (fe) for each drug that required dose adjustment. For most 
drugs, fe values have been present in the literature.
RESULTS
Pharmacokinetic analysis using applications built using the Visual 
Basic.Net programming language for the determination of drug doses 
in patients with diabetes mellitus complications of renal failure in 
RSUD Dr. Pirngadi Medan. The study obtained 320 cases but only 40 
patients met the complete criteria consisting of 16 male and 24 female, 
10 patients aged 41-50 years, 20 patients aged 51-60 years and 10 
patients with 61-70 years of age, 2 patients with creatinine clearance 
30-50 mL/min and the rest <30 mL/min. Based on data on the use of 
drugs to 40 patients, there are 6 types of drugs which are drugs that 
are largely excreted through the kidney in the form of unchanged 
ceftriaxone (fe = 40–65% iv, 18 cases), furosemide (fe = 74%, 19 cases), 
ranitidine (fe = 50% oral, >70% iv, 24), ciprofloxacin (fe = 40–50% oral, 
70% IV, 8 cases), captopril (fe = 75%, 16 cases), and metformin (fe = 
60%, 7 cases). Patient’s demography and cases of medication can be 
seen in Table 1 and Table 2.
DISCUSSION
After using the visual basic programming language application as 
shown in Fig. 1, a drug dose adjustment for patients with chronic renal 
impairment in Figs. 2-8 is obtained. IMethod 2 is not be used in this study 
because creatinine measurement is generally performed only once. The 
patient also excludes obese patients so that Figs. 2-5shows a comparison 
chart between the usual dosage, the dose administered in the hospital, 
and the dose of calculation based on creatinine clearance using method 1.
The use of ranitidine was used by 24 patients from the 40 patients 
observed. Based on pharmacokinetic calculations, 3 cases of 
intravenous administration of P3 (doses administered 100 mg over 
a creatinine clearance dose count of 90 mg), P8 (dose administered 
150 mg over creatinine clearance dose of 120 mg), P38 (given dose 
100 mg over the calculated creatinine clearance dose of 90 mg), 
whereas 1 case is P22 (given 200 mg dose over creatinine clearance 
dose of 180 mg). The differences between the doses administered 
and the dose calculations based on creatinine clearance were not 
significantly different (P < 0.01). Fig. 2 shows that the physician at the 
Pirngadi Hospital has attempted to reduce the dose of administration 
of the drug to the diabetic patient with renal impairment, but this is 
done not on the exact pharmacokinetic calculation so that there are 
4 cases of administration doses that exceed the pharmacokinetic dose 
calculation and 15 cases less than the dose which should be given 
based on the patient’s creatinine clearance calculations. Basic.net 
visual applications can quickly calculate the dose that should be given 
to the patient based on the patient’s creatinine clearance so that no 
errors in the dosage drug of the diabetic patients for renal failure are 
made [9]. Ranitidine is excreted through the kidneys in unchanged 
about 50% for oral and >70% for intravenous. Patients with creatinine 
clearance <50 mL/min recommended oral dose is 150 mg/day, with 
increased dose monitoring to 150 mg/12 h, while for intravenous 
doses, some countries have different recommendations. In the UK, 
the recommended intravenous dose is 25 mg/day with a customized 
frequency, whereas in the United States, the recommended 
intravenous dose is 50 mg/day for 18/24 h, which may increase easily 
to every 12 h or more often if necessary [10].
Ciprofloxacin is a drug with a wide therapeutic index that has a fairly high 
level of safety, but doses in patients with renal failure should be adjusted, 
especially patients with creatinine clearance <50 mL/min to avoid elevated 
levels of the drug in the blood that will aggravate kidney work [11]. The 
result data showed 2 of 8 cases of ciprofloxacin use exceeded the calculated 
dose based on renal function of patients using pharmacokinetic equation, 
i.e., on P3 (dose administered 1000 mg over the creatinine clearance 
dose count of 400 mg) and P19 (dose administered 1000 mg over dose 
calculation of creatinine clearance of 600 mg). The difference between 
the doses administered and the dose of pharmacokinetic calculation in 
the above 2 cases was significantly different (P < 0.01), while the other 6 
gave the same result between the dosing and the calculated dose based on 
creatinine clearance. Doctors at the hospital have attempted to make dose 
adjustments for these patients with renal failure complications, but there 
are still 2 cases (25% error) in administering the dose, and of course, it 
is caused by the complexity of calculating the dose based on the patient’s 
creatinine clearance so that it requires a computer application which 
makes it easier for the physician to take medical action [9].
Fig. 1: Flow of process application
Fig. 2: Implementation of individual dose calculation application [9]
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Furosemide is indicated as diuretics for Edema and hypertension at 
doses of 20–40 mg/day for Udem, 80–120 mg/day for resistant Udem, 
and 40–80 mg/day for hypertension therapy. For patients with renal 
failure, a larger dose of furosemide is 40–200 mg/day [12]. This is 
because in patients with renal failure, there will be a decrease in 
bioavailability of furosemide [13]. Approximately 74% of furosemide 
is secreted in intact form through the kidneys [2]. Adjustment of 
furosemide dose for diabetic patients with renal failure was not 
calculated by the pharmacokinetics equation, and the patient’s dose 
adjusted simultaneously with the patient’s clinical response [10]. 19 of 
19 cases of furosemide use are given in excess if calculated using clinical 
pharmacokinetics equations, and it is still considered safe because 
patients with kidney disorders have fluid accumulation but needs 
easier monitoring of drug delivery using VB.NET program integrated 
with pharmacokinetic formula.
15 of the 40 patients used ceftriaxone with a dose of 2 g/day, 
2 patients with a dose of 1 g/day, and 1 patient with 4 g/day with 
intravenous administration (bolus). Pharmacokinetics ceftriaxone 
does not change in low-stage renal failure to moderate stage, but 
Fig. 3: Usual doses of ranitidine, doses administered at the hospital and dose calculations based on creatinine clearance
Fig. 4: Usual doses of ciprofloxacine, doses administered at the hospital and dose calculations based on creatinine clearance
Fig. 5: Usual doses of furosemide, doses administered at the hospital and dose calculations based on creatinine clearance
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its half-life may be prolonged in severe stage renal failure to end-
stage renal failure. Dose adjustment is required for patients with 
severe renal failure, especially those with creatinine clearance of 
<10 mL/min with doses not exceeding 2 g/day [14]. 18 cases of 18 
ceftriaxone administration exceeded the dose of pharmacokinetic 
calculation based on the patient’s creatinine clearance using a 
computer dosing program [9].
Metformin is excreted in an unchanged form through the kidney of 
about 60% [10]. Metformin administration in patients with renal 
failure should be noted primarily in patients with creatinine clearance 
below 45 mL/min, whereas for patients with creatinine clearance 
<30 mL/min metformin use is avoided to avoid the effects of lactic 
acidosis. Lactic acidosis is a condition in which blood and acidity of the 
tissues increase as lactic acid accumulation increases.
Fig. 6: Usual doses of ceftriaxone, doses administered at the hospital and dose calculations based on creatinine clearance
Fig. 7: Usual doses of metformine, doses administered at the hospital and dose calculations based on creatinine clearance
Fig. 8: Usual doses of captopril, doses administered at the hospital and dose calculations based on creatinine clearance
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Captopril is excreted mostly by urine, 40–65% in unchanged form. In patients 
with renal failure, peak plasma concentration of captopril will increase 
2.5 times compared to patients with normal renal function [15]. The dose of 
captopril should be adjusted according to renal function of diabetic patients 
with renal failure, especially patients with creatinine clearance <30 mL/min. 
The results showed that 16 cases of captopril use were less than the 
dose of pharmacokinetic calculations. In this case, doctors in hospitals 
have made efforts to decrease the dosage of captopril to avoid toxic effects 
but because the dose reduction is not mathematically calculated so that the 
dose of administration is considerably less than the dose that should be 
given.
CONCLUSION
Visual basic.net. succeed to calculate the individual dose for diabetic 
patients with renal failure quickly and easily, so VB.NET dose calculation 
program is needed by doctors in performing the right dose in patients 
with diabetes complications of kidney failure.
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Table 2: Cases of Medication
Medication n Excessive dosage Less dosage %
Ranitidine 24 4 15 16.7
Ciprofloxacin 8 2 - 25
Metformin 7 - 2 0
Captopril 16 - 16 0
Furosemide 19 19 - 100
Ceftriaxone 18 18 - 100
